AMAmir Mehdizadeh

Amir Mehdizadeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amir Mehdizadeh has a total of 268 co-authors. Here are the top co-authors by number of shared publications:

  • Masoud Darabi

    Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    20 shared publications
  • Mehdi Yousefi

    Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    8 shared publications
  • Shabnam Fayezi

    Department of Gynecologic Endocrinology and Fertility Disorders, Women’s Hospital, Ruprecht-Karls University of Heidelberg, Heidelberg, Germany

    7 shared publications
  • Maghsod Shaaker

    E Department of Biochemistry and Clinical Laboratories , School of Medicine, Tabriz University of Medical Sciences , Tabriz , Iran

    6 shared publications
  • Masoud Darabi

    Division of Experimental Oncology, Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Lübeck, Germany

    6 shared publications
  • Mortaza Raeisi

    Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    6 shared publications

Latest Publications

  • Open Access

    Phenotypic and functional similar ities between mesenchymal stem cells and fibroblasts in cancer

    by Masoud Asgari, Hengameh Khadivi Heris, Mortaza Raeisi, Tamanna Tariverdian, Narjes Seddighi, Khadijeh Abbasi, Zahra Hasanzadeh, Amir Mehdizadeh

  • Unpacking the lipid–immune axis in health and disease

    by Mortaza Raeisi, Mehdi Yousefi, Roza Motavalli, Ali Hassanzadeh, Narjes Seddighi, Maghsoud Mehri, Shiva Ebrahimi, Amir Mehdizadeh, Khadijeh Abbasi

    The lipid–immune system relationship represents an important but overlooked axis of inflammation and host defense regulation. Radically different from an energy source or structural component, lipids influence immune cell regulation, signaling and inflammatory responses. This narrative review provides a broad overview of the role lipids play in immune regulation in both healthy and pathogenic states. We initiate the review by summarizing the role of a variety of lipid classes in immune cell biology, with an emphasis on explaining how lipid composition and metabolism influence both innate and adaptive immunity. Next, we analyze the role that lipid‐based mediators eicosanoids, resolvins and ceramides play in regulating inflammatory and pro‐resolving pathways. We observe dietary and circulatory lipids additionally direct the immune response and modulate the resolution of inflammatory processes. In diseases characterized by prolonged and persistent immune activation and low‐grade inflammation, such as atherosclerosis, obesity, type 2 diabetes and autoimmune diseases, impaired lipid metabolism ultimately aids this persistent state of immune activation. Moreover, we also consider the emergent role of the lipid‐immune interface in infectious disease, demonstrating ways in which pathogens can hijack or modify lipid metabolism to escape the host immune response. We cover the potential therapeutic implications of lipid–immune interactions, noting potential strategies using statins, omega‐3 fatty acids, or specialized lipid mediators, all with the objective of modulating inflammation rather than broad immunosuppression. Finally, we also identify important knowledge gaps and will suggest avenues for future research, particularly the need for more integrated lipidomic and immunologic studies.


  • Open Access

    The interplay between non-coding RNAs and Wnt signaling pathway in leukemia: A narrative review

    by Reza Biglari, Majid Farshdousti Hagh, Khadijeh Abbasi, Maghsood Shaaker, Amir Mehdizadeh

    Leukemias are heterogeneous hematologic malignancies that involve dysregulated proliferation and impaired differentiation of hematopoietic cells. The Wnt signaling pathway, which regulates hematopoietic stem cell self-renewal and lineage commitment, is dysregulated across leukemia subtypes. Non-coding RNAs (ncRNAs), which include microRNAs, long non-coding RNAs (lncRNAs), and circular RNAs, have been identified as important post-transcriptional and epigenetic regulators of oncogenic signaling networks. There is growing evidence for a complex, bidirectional relationship between ncRNAs and the Wnt/β-catenin pathway, but this has not yet been summarized or integrated into the context of leukemia. This study examines how ncRNA manipulation of core Wnt components – β-catenin, Frizzled receptors, and Dvl (dishevelled) proteins – affect leukemic cell survival, proliferation, stemness, and treatment resistance. Furthermore, we discuss reciprocal regulation, in which Wnt stimulation affects ncRNA production, forming feed-forward loops that promote leukemogenesis. By synthesizing disparate findings from studies investigating ncRNA and Wnt signaling mechanisms across leukemia subtypes, we identify critical mechanistic gaps in the literature, as well as opportunities and controversies that could be that could be leveraged in evaluating ncRNA–Wnt interactions as diagnostic and therapeutic targets. This review presents a comprehensive study integrating ncRNA biology and Wnt-driven leukemic development in order to identify crucial insights into disease vulnerabilities and future research initiatives.

  • Open Access

    Investigating the effect of stearoyl-coenzyme desaturase 1 Inhibition on inflammatory and anti-inflammatory patterns in luminal A breast cancer patients’ peripheral blood mononuclear cells

    by Neda Naghashi, Esmaeil Babaei, Zohreh Sanaat, Amir Mehdizadeh

    Purpose Breast cancer (BC) is the most prevalent female cancer globally. A key feature of cancer cells is a remarkable alteration in lipid composition, notably an enrichment in monounsaturated fatty acids. This change results from the upregulated expression of enzymes involved in fatty acid metabolism, such as stearoyl-CoA desaturase 1 (SCD1), which may affect immune-related responses. Patients and methods In the present study, 20 patients with luminal A BC and 20 healthy controls were included based on diagnostic criteria. Then, 10 ml of peripheral blood was retrieved from each participant, and peripheral blood mononuclear cells (PBMCs) were isolated, pooled, and cultured in RPMI 1640 medium. The treatment and control groups were then treated with 3 µM of the SCD1 chemical inhibitor and DMSO, respectively, for 48 h. The alteration in inflammatory markers IL-17 and TNF-α, anti-inflammatory markers IL-10 and TGF-β, inflammatory differentiation markers RORγt, and anti-inflammatory differentiation markers FOXP3 were assessed through Real-time PCR. Furthermore, the amount of the respective protein was measured through the enzyme-linked immunosorbent assay method. Results Chemical inhibition of SCD1 resulted in a significant downregulation of IL-17/TNF-α and upregulation of IL-10/TGF-β expression in the patient group. Additionally, a significant upregulation of FOXP3 was observed in BC patients after SCD1 inhibition. RORγt expression was also decreased in healthy individuals after SCD1 inhibition, with no effect on the patient group. Conclusion The results of this study suggest that SCD1 may act as a potential biomarker in the context of immune response.


  • Open Access

    Fatty acid composition of lipid fractions in white- and brown-like adipocytes derived from human mesenchymal stem cells

    by Khadijeh Abbasi, Amir Mehdizadeh, Hamed Hamishehkar, Mohammad Nouri, Masoud Darabi

    White and brown adipocytes differ markedly in lipid composition and metabolic function. White adipocytes primarily serve as energy storage depots, whereas brown adipocytes are mitochondria-rich and specialized for thermogenesis. However, the lipidomic profiles of white-like (WLAs) and brown-like adipocytes (BLAs) differentiated from human mesenchymal stem cells (MSCs) remain incompletely characterized. Human adipose-derived MSCs were differentiated into WLAs and BLAs. Lipid fractions were isolated and analysed by gas-liquid chromatography. Fatty acid composition data were used to calculate indices of stearoyl-CoA desaturase-1 (SCD1) activity, elongation, and ω6 synthesis. Compared to MSCs, BLAs showed consistently elevated oleate (≥4.2-fold) and stearate (≥2.3-fold), along with reduced palmitate (≤-20%) and linoleate (≤-28%) across phospholipid, triglyceride, and free fatty acid fractions. WLAs versus MSCs showed similar trends, with oleate increasing up to 15-fold and palmitate decreasing by 67-82% depending on the lipid class. SCD1 activity and elongation indices were elevated in WLAs (SCD1: up to 4.7-fold; elongation: up to 28-fold). The ω6 synthesis index was also increased in triglyceride and free fatty acid fractions of WLAs (≥3.3-fold), but markedly suppressed in BLAs (≤-88.7%). WLAs and BLAs differentiated from MSCs exhibit distinct lipid profiles and inferred enzymatic activity patterns, reflecting their respective capacities for lipid storage and metabolic flexibility. These findings provide a foundation for future translational research aimed at targeting adipose tissue in obesity and metabolic diseases.


  • The Effect of Chemotherapeutic Agents Used in Breast Cancer Treatment on the Hepatic Lipotoxicity

    by Maghsoud Shaaker, Masoud Darabi, Gholamreza Dehghan, Mohammad Ali Hosseinpour Feizi, Amir Mehdizadeh

    Breast cancer (BC) is the most common type of cancer in women. Researchers have studied various types of inhibitors of the MAPK/ERK signaling pathway, which plays an important role in the growth of BC cells. PD98059 is a potent and selective inhibitor of MEK, which may have potential application in the combined treatment of BC along with doxorubicin and Taxotere. The aim of this study was to provide a new insight into hepatotoxicity caused by doxorubicin, Taxotere, and PD98059 mono/combination therapy in a hepatoma in vitro model. HepG2 cells were treated with appropriate doses of used drugs. The expression of FASN and SCD1 lipogenic genes was measured by real-time PCR. The fatty acid composition PL and triglyceride fractions were analyzed using gas–liquid chromatography. The indicators of oxidative stress and antioxidant defense systems were measured by the calorimetric method. Doxorubicin and Taxotere significantly decreased FASN expression and increased SCD1 expression. Additionally, the combination of PD98059 alone, in combination with doxorubicin, or doxorubicin and Taxotere significantly increased the expression of SCD1. However, the combination of PD98059 and Taxotere significantly decreased this expression. PD98059 alone also dramatically increased the expression of FASN. In the PL fraction, doxorubicin, Taxotere, or PD98059 increased the percentage of saturated fatty acids and decreased the relative amount of unsaturated fatty acids alone. The doxorubicin + PD98059 combination also enhanced the effect of doxorubicin on PL SFAs and UFAs. Taxotere also reduced the SFAs and increased UFAs in the triglyceride fraction, which was also neutralized by PD98059 addition. Based on these findings, increased expression of SCD1 and elevated levels of SFAs in lipid fractions may indicate the possibility of hepatic lipotoxicity in BC patients, which necessitates the narrow monitoring of steatohepatitis in these patients.

  • miRNAs as emerging predictors of tamoxifen resistance in breast cancer

    by Elmira Aboutalebi Vand Beilankouhi, Reza Safaralizadeh, Babak Nejati, Zohreh Sanaat, Jalil Vaez Gharamaleki, Ali Esfahani, Nasrin Gholami, Parvin Sarbakhsh, Jamal Mohammadian, Amir Mehdizadeh

    One of the most common cancers among women worldwide is breast cancer (BC). Many BC patients express estrogen receptors (ER), and estrogens are critical for their survival, development, and invasion. Therefore, the ability to produce and respond to estrogen, known as endocrine function, represents a potential drug treatment for ER-positive BC. Tamoxifen (TAM), a selective ER modulator, is widely used in hormone-based therapy. However, the emergence of TAM resistance is a significant clinical challenge that often leads to recurrence, progression, and metastasis. Despite its importance, there are currently no reliable biomarkers to predict patient response to hormone-based therapies. MicroRNAs (miRNAs), small non-coding RNAs, have emerged as key regulators in various physiological and pathological processes, including BC initiation, progression, and resistance to therapy. Recent studies highlight the potential of specific miRNAs as predictive biomarkers for TAM resistance. Notably, miR-382-3p and miR-93 are significantly upregulated in TAM-resistant patients, while miR-182-3p is increased in TAM-sensitive patients. Other studies have also shown that circulating miR-221/222 expression can predict recurrence and resistance to tamoxifen treatment in BC patients. Therefore, testing miR-221/222 expression in patients with ductal BC undergoing tamoxifen treatment is recommended to rapidly identify the risk of tamoxifen resistance and enhance treatment efficacy. These findings emphasize the diagnostic and prognostic potential of miRNAs in BC, especially in identifying patients at risk of developing resistance to hormone-based therapies, and provide insights that could enhance personalized treatment strategies and improve treatment outcomes for BC patients.


  • Impact of lymphocyte immunotherapy (LIT) on fertility rates in recurrent pregnancy loss (RPL) women with antinuclear antibodies: A randomized clinical trial

    by Mohsen Dashti, Amin Kamrani, Zahra Shahir-Khajeh, Javad Ahmadian Heris, Leili Aghebati-Maleki, Shahla Danaii, Forough Chakari-Khiavi, Behnam Shahriar, Mehrin Sadough, Sina Baharaghdam, et al.


  • Investigation of circulating miR-182-3p, miR -382-3p and miR -93, miR -142-3p involved in tamoxifen resistance and sensitivity in luminal-subtype breast cancer patients: a case–control study

    by Elmira Aboutalebi Vand Beilankouhi, Zohreh Sanaat, Mohammad Ali Hosseinpour Feizi, Amir Mehdizadeh, Reza Safaralizadeh

    Breast cancer (BC) commonly expresses estrogen receptors (ERs); hence, endocrine therapy targeting ERs is considered an effective treatment. Tamoxifen (TAM) resistance is an essential clinical complication leading to cancer progression and metastasis. This study investigated MicroRNAs (miRNAs) potentially implicated in drug resistance (miR-182-3p, miR-382-3p) or sensitivity (miR-93, miR- 142- 3p). This study aimed to provide new insights into serum microRNA expression profiles in BC. This case-control study included patients with luminal-A BC who received TAM for approximately one year. The case and control groups included 40 patients with or without local recurrence or metastasis. The expression levels of miR-182-3p, miR-382-3p, miR-93, and miR-142-3p in plasma samples were measured using real-time PCR with target-specific primers. The multivariate model of miR-93 (p = 0.0002), miR-182-3p (p = 0.0002), and miR-382-3p (p = 0.0028) demonstrated higher predictive power for TAM resistance. The only significant association was observed between miR-382-3p expression and lymphovascular invasion (LVI) (p = 0.0314). Moreover, lower expression levels of miR-93 and miR-382-3p were observed in the TAM-sensitive group compared to the TAM-resistant counterparts (p = 0.0002 and p = 0.0028, respectively). In contrast, the expression level of miR-182-3p was significantly higher in the TAM-sensitive group compared to the TAM-resistant group (p = 0.0002). receiver operating characteristic (ROC) curve analysis also indicated the expression of miR-182-3p (p < 0.001; area under curve (AUC): 0.753), miR-382-3p (p = 0.0028; AUC: 0.697), and miR-93 (p < 0.001; AUC: 0.762) as predictive markers for TAM resistance. Multivariate models based on miR-182-3p, miR-382-3p, and miR-93 can predict the response to hormone therapy. Measuring these miRNAs is also recommended for patients with luminal-subtype BC undergoing TAM therapy.


  • Open Access

    Cytokine-induced killer cells: new insights for therapy of hematologic malignancies

    by Faezeh Ghanbari Sevari, Amir Mehdizadeh, Khadijeh Abbasi, Seyyed Sina Hejazian, Mortaza Raeisi

    Cytokine-induced killer (CIK) cells are a novel subgroup of immune effectors, classified as one of the modified T cell-mediated arms for immunotherapy. These cells exert MHC‐unrestricted cytotoxicity against both hematological and solid malignancies with low incidence of treatment‐related severe complications. This study reviews the application of CIK cells in treating cases with hematologic malignancies. CIK cells consist of CD3+/CD56+ natural killer (NK) T cells, CD3−/CD56+ NK cells, and CD3+/CD56− cytotoxic T cells. In this regard, the CD3+/CD56+ NK T cells are the primary effectors. Compared with the previously reported antitumor immune cells, CIK cells are characterized by improved in vitro proliferation and amplification, enhanced migration and invasive capacity to tumor region, more significant antitumor activity, and a broader antitumor spectrum. CIK cells can also induce death in tumor cells via numerous pathways and mechanisms. Hence, CIKs-based therapy has been used in various clinical trials and has shown efficacy with a very low graft versus host disease (GVHD) against several cancers, such as hematologic malignancies, even in relapsing cases, or cases not responding to other therapies. Despite the high content of T cells, CIK cells induce low alloreactivity and, thus, pose a restricted threat of GVHD induction even in MHC-mismatched transplantation cases. Phase 1 and 2 clinical trials of CIK cell therapy have also highlighted satisfactory therapeutic advantages against hematologic cancers, indicating the safety of CIK cells even in haploidentical transplantation settings. CIK cells have shown promising results in the treatment of hematologic malignancies, especially in combination with other antitumor strategies. However, the existing controversies in achieving desired clinical responses underscore the importance of future studies.